Skip to main navigation
Orchestra BioMed logo

Close

Investor Relations
  • Who We Are
    • Our Approach
    • Our People
    • Careers
  • Our Innovations
    • Pipeline
    • Therapeutic Areas
    • Virtue® SAB
    • BackBeat CNT™
    • FreeHold Retractors
  • Investor Relations
  • News & Events
    • News Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Corporate Governance
    • Documents & Charters
    • Leadership Team
    • Board of Directors
    • Committee Composition
  • Financial & Filings
    • SEC Filings
    • Annual Reports and Proxy Satements
  • IR Resources
    • Email Alerts
    • Contact IR
  • Contact Us
Menu - sns
Twitter Linkedin

Investor Relations

News Releases

Orchestra BioMed Debuts as Nasdaq-Traded Company with Lead Programs Targeting Hypertension and Artery Disease and Novel Partnership-Enabled Business Model
January 27, 2023
Business combination with Health Sciences Acquisitions Corporation 2, a special purpose acquisition company sponsored by an affiliate of RTW Investments, LP, completed on January 26, 2023 The combination was announced simultaneously with Orchestra’s strategic collaboration with Medtronic to develop
Orchestra BioMed™ Announces Presentation of Positive Long-Term Clinical Results from MODERATO II Control Patients Crossover Extension Study of BackBeat CNT™ at TCT 2022
September 20, 2022
Statistically significant mean reductions of 10.3 mmHg in 24-hour ambulatory systolic blood pressure and 11.7 mmHg in ambulatory pulse pressure after 6 months of therapy in control patients who crossed over to BackBeat CNT following completion of the randomized portion of the MODERATO II study New
Orchestra BioMed™ Announces Strategic Collaboration, Closing of $110 Million Private Equity Financing and Plans to List on Nasdaq Through Merger with Health Sciences Acquisitions Corporation 2
July 5, 2022
Strategic collaboration with Medtronic to develop BackBeat Cardiac Neuromodulation Therapy™ as potential integrated hypertension treatment for cardiac pacemaker patients Investors in $110 million Series D financing include Medtronic and Terumo as well as lead investor RTW Investments and founding
Orchestra BioMed™ Announces Presentations at TCT 2021 of Positive Long-Term Clinical Results from the MODERATO II Study Showing the Significant Clinical Impact of BackBeat CNT™ on Isolated Systolic Hypertension and Pulse Pressure
November 5, 2021
BackBeat CNT treated patients experienced a mean reduction of 17.5 mmHg in office systolic blood pressure measured 24-months following therapy activation. Patients with Isolated Systolic Hypertension (ISH) treated with BackBeat CNT experienced clinically meaningful and statistically significant
Orchestra BioMed™ Announces Peer-Reviewed Publication of MODERATO II Study Results Showing a Statistically Significant Reduction in Blood Pressure in Pacemaker-Indicated Patients Treated with BackBeat Cardiac Neuromodulation Therapy™
August 17, 2021
Double-blind, randomized trial data show a clinically meaningful and statistically significant net reduction of 8.1 mmHg in 24-hour ambulatory systolic blood pressure at 6 months in treated vs. control patients Very high (85%) response rate to therapy despite 81% of treated patients having isolated
Orchestra BioMed™ Announces Clinical Data Demonstrating a Significant and Sustained Reduction in Blood Pressure in MODERATO II Control Patients After Crossover to BackBeat Cardiac Neuromodulation Therapy™
July 30, 2021
Clinically meaningful and statistically significant reduction in systolic blood pressure is consistent with the decrease previously observed in the study treatment group during the same time period. Ambulatory Systolic Blood Pressure (aSBP) decreased by an average of 10.3 mmHg (p
Orchestra BioMed™ Announces Clinical Data Showing Significant and Sustained Reduction in Systolic Blood Pressure Out to Two Years with BackBeat Cardiac Neuromodulation Therapy™
May 17, 2021
Clinically meaningful and statistically significant reduction of 16.6 mmHg in systolic blood pressure out to two years 88% of the treated patients had isolated systolic hypertension (ISH) 70.6% of all treated patients and 80% of treated ISH patients had their blood pressure under control at 24
How Can Early-Stage Medical Device Companies Survive Market Turmoil?
May 23, 2020
Medical Device and Diagnostic Industry (MD+DI) David Hochman, founder and CEO of Orchestra BioMed, shares how the company's risk-reward sharing business model has helped it stay afloat during the coronavirus pandemic. CLICK HERE FOR FULL ARTICLE
Daniel Burkhoff, MD, PhD, presented data from our MODERATO II double-blind, randomized study of BackBeat Cardiac Neuromodulation Therapy ™ at the 2020 Heart Rhythm Scientific Sessions online
May 8, 2020
Event:  2020 Heart Rhythm Scientific Sessions online Webcast:  HTTPS://CSLIDE-US.CTIMEETINGTECH.COM/HRS20/ATTENDEE/EPOSTER/POSTER/1407?Q=BURKHOFF
Orchestra BioMed™ Enhances Management Team with Appointment of Regulatory Affairs and Combination Product Expert Bob Laughner as Vice President, Regulatory Affairs
April 28, 2020
New Hope, PA - Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing transformative therapeutic products for large unmet needs in procedure-based medicine, today announced the appointment of Bob Laughner, an expert in global regulatory affairs for

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Current page 2
  • Page 3
  • Page 4
  • Page 5
  • Next page next ›
  • Last page last »
Displaying 11 - 20 of 47
Orchestra BioMed logo
  • Footerlink - who we are

    Who We Are Our Approach Our People Careers
  • Footerlink - our innovations

    Our Innovations Pipeline Therapeutic Areas Virtue® SAB BackBeat CNT™ FreeHold Retractors
  • Footerlink - news & events

    Investor Relations Overview News & Events Stock Information Corporate Governance Financial & Filings IR Resources
  • Footerlink - contact us

    Contact Us
Menu - sns
Twitter Linkedin

© 2023 Orchestra BioMed Inc. Virtue®, BackBeat CNT™ FreeHold Duo®, FreeHold Trio® and Orchestra BioMed™ are trademarks of Orchestra BioMed.
All other trademarks are trademarks of their respective owners.
SM-0020 Rev 01

Btn - disclaimer

Disclaimer